Home > Press > Dr. Amir Zalcenstein, MBA, appointed SoluBest's CEO
SoluBest appoints Dr. Amir Zalcenstein as CEO
Dr. Amir Zalcenstein, MBA, appointed SoluBest's CEO
Israel | Posted on June 28th, 2010
SoluBest, a company developing an easy-to-integrate technological platform for solving the problem of drug insolubility, has appointed Dr. Amir Zalcenstein as new CEO.
Dr. Zalcenstein joined SoluBest in 2007 as Business Development Manager and was appointed to Senior Director of Business Development in 2008. Prior to joining SoluBest he worked with Ernst & Young's GIA division as a senior consultant. He holds an MBA of Technion (Haifa, Israel) and a doctoral degree in cancer genetics from the Weizmann Institute of Science (Rehovot, Israel). His post-doctorate dealt with nanotechnology.
"I am very happy to take over as CEO," said Amir Zalcenstein, "as SoluBest‘s technology is meeting an increasing demand by global pharmaceutical companies who need to solve the problem that over 40% of the drugs on the market and up to 60% of drugs currently in development are insoluble."
"These are exciting times for SoluBest," said Dr. Ronnie Hershman, Chairman of the Board of SoluBest. "We have never been closer to achieving our business goals: Amir has been effective with our business development over the last three years, and was instrumental in launching SoluBest‘s very successful 'free formulation initiative.‘ With his vision and leadership, we feel he is the right person at the right time to advance the company to significant revenue generation and further business opportunities. I fully expect Solubest to enter a period of profitability and growth under his leadership. We support him fully and wish him much success."
SoluBest‘s "free formulation initiative" offers interested parties to formulate up to 5 molecules for free, with no obligation and no cost except the cost of the API. Already, the initiative led to various collaboration agreements, among them top 10 global pharmaceutical and agrochemical companies and to marketing agreements with leading CROs from the UK an the US.
SoluBest is a clinical stage developer of enabling drug delivery technologies, established in 2001 with the intention of developing smart polymer, self-assembling nano-particle constructs. The company is located at the Weizmann Science Park in Ness Ziona, Israel, and employs a team of experienced polymer and analytical chemists.
SoluBest is currently completing a series D financing round, raising $1.5M, of which $1.3M have been raised already.
About SoluBest‘s Solumer™ Technology
SoluBest’s proprietary Solumer™ process addresses the issue of drug insolubility by creating therapeutic and nutraceutical formulations in which active drug molecules are uniquely interwoven with FDA-approved polymers. Once in the body, these oral, solid-dosage formulations disintegrate into stable nano-particles, potentially increasing drug solubility and oral absorption, thus improving the bio-performance of insoluble drugs and nutritional actives.
SoluBest's technology is designed to provide significant advantages, among others:
• Improved solubility of a broad range of small molecules,
• Freedom to operate per product,
• Superior bio-availability as demonstrated in two exploratory clinical trials,
• Ease of production, using existing equipment with little or no modification,
• Quick turnaround through rapid feasibility and scale-up time,
• Low regulatory risk by using safe and FDA-approved polymer excipients and environmentally safe solvents.
For more information, please click here
Dr. Amir Zalcenstein, CEO
Weizmann Science Park
18 Einstein Street
Ness Ziona 74140, Israel
T: +972 8 940 3023 x102
F: +972 8 930 2878
Copyright © SoluBest
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
News and information
Graphene reduces wear of alumina ceramic March 26th, 2015
FEI Technology Award of the German Neuroscience Society Goes to Benjamin Judkewitz of the University of Berlin: Bi-annual award honors excellence in brain research during the German Neuroscience Society’s Annual Meeting, held 18-21 March 2015 March 26th, 2015
SUNY Poly & M+W Make Major Announcement: Major Expansion To Include M+W Owned Gehrlicher Solar America Corporation That Will Create up to 400 Jobs to Develop Solar Power Plants at SUNY Poly Sites Across New York State March 26th, 2015
Hong Kong Investors Bullish on Dais Analytic Invest $5.75M, Provide $60M Contract, and Create New Joint Venture Company March 26th, 2015
Industrial Nanotech, Inc. Announces Next Large Order from the Oil and Gas Industry March 26th, 2015
Quantum compute this -- WSU mathematicians build code to take on toughest of cyber attacks: Revamped knapsack code offers online security for the future March 26th, 2015
Thousands of atoms entangled with a single photon: Result could make atomic clocks more accurate March 26th, 2015
Square ice filling for a graphene sandwich March 26th, 2015
Nanofilm Appoints Senior Sales/Marketing Executives: Don Tecco, Director of Optical Sales, North America and Rex Talbott, Business Director Optical Products March 23rd, 2015
KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015
SouthWest Nanotechnologies CEO Dave Arthur Appointed to the Board of Affiliates of Rice University Professional Science Master’s Program February 13th, 2015
Nexeon Board Changes Announced January 29th, 2015